Status:
ACTIVE_NOT_RECRUITING
Identification of a Biomarker Predictive of Evolution of Parkinson Disease
Lead Sponsor:
Nantes University Hospital
Conditions:
Parkinson Disease
Eligibility:
All Genders
40-67 years
Phase:
PHASE2
Brief Summary
Phase II, Open-labeled, Prospective, Multi-center study of assessing the link between microglial activation and dopaminergic denervation kinetics in the early stage of Parkinson disease, by using the ...
Detailed Description
The Parkinson's disease ( MP) is a frequent but heterogeneous neurodegenerative disease in term of clinical presentation(display) and evolutionary profile. The therapeutic coverage(care) of the patien...
Eligibility Criteria
Inclusion
- Patients having a Parkinson's disease diagnosed according to the criteria UKPDSBB.
- Diagnosis done less than three years before the date the inclusion.
- Patient Age at diagnosis : between 40 and 65 years.
- Absence of clinical arguments for an associated neurovascular pathology.
- Written consent obtained.
- HAB polymorphism in the genotyping of TSPO gene.
- Brain MRI without following abnormalities: cortical or sub-cortical atrophy or hippocampal atrophy (Scheltens score ≥2), vascular encephalopathy (Fazekas score \> 2, \> 10 microbleed) or showing signs in favour of atypical parkinson syndrome.
Exclusion
- Pregnant woman
- Minor
- Adult protected by the law
- Contraindication to PET-scan
- Contraindication to brain MRI
- History of inflammatory or dysimmune chronic disease
- History of psychiatric disease or drug addiction
- History of cognitive disorders (MMS\<26)
- Hypersensibility to iodine derivates or one of these components
- Long-term Treatments which can interfere in neuroinflammation process
- Treatments / substances susceptible to interfere with the 18F-DPA-714
- TSPO gene Polymorphisms rs6971 corresponding to groups of affinity of low affinity (LAB=Low Affinity Binder) or moderated MAB = Mixed Affinity Binder)
- Modification of diagnosis of Parkinson disease during follow-up, in particular towards an atypical parkinson-like syndrome
Key Trial Info
Start Date :
April 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 6 2024
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT03230526
Start Date
April 16 2018
End Date
May 6 2024
Last Update
April 25 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nantes
Nantes, France
2
Centre Eugène Marquis
Rennes, France
3
CHU de Rennes
Rennes, France
4
CHU de Tours
Tours, France